PresentationsA First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Oral BTK Degrader With Immunomodulatory Activity, in Patients With Relapsed and Refractory B-Cell Malignancies By AldenMC Production / June 3, 2022
PresentationsA First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Solid Tumors By AldenMC Production / June 3, 2022
PresentationsApplication of DNA-Encoded Libraries to Discover Small Molecules for E3 Ligase Modulation By AldenMC Production / April 28, 2022
PresentationsInhibitors of the E3 Ubiquitin Ligase CBL-B Promote Potent T and NK Cell Mediated Anti-Tumor Response By AldenMC Production / April 19, 2022
PresentationsConcurrent degradation of BTK and IMiD neosubstrates by NX-2127 enhances multiple mechanisms of tumor killing By AldenMC Production / April 12, 2022
PresentationsEx-vivo inhibition of CBL-B with a novel small molecule inhibitor, NX-0255, enhances persistence and anti-tumor activity of adoptively transferred CD8+ T cells in mouse tumor models By AldenMC Production / April 8, 2022
PresentationsNX‑5948, a Selective Degrader of BTK With Activity in Preclinical Models of Hematologic and Brain Malignancies By AldenMC Production / December 12, 2021
PresentationsNX‑0255, a Small‑Molecule CBL‑B Inhibitor, Expands and Enhances Tumor‑InfiltratingLymphocytes for Use in Adoptive Cancer Immunotherapy By AldenMC Production / November 12, 2021
